EDX Medical signs distribution agreement with Caris Life Sciences

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced it has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation AI TechBio and precision medicine company.

Under the agreement, EDX Medical and Caris will work together on a mutually exclusive basis in the United Kingdom (UK) and Nordic countries for a minimum of three years to distribute Caris’ portfolio of advanced and comprehensive molecular profiling services for clinical and research use.

Caris’ best-in-class molecular profiling, combined with proprietary artificial intelligence, enables physicians to make more precise and individualized cancer treatment decisions.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
EDX Medical Group plc

More articles like this

EDX Medical Group plc

Genetic testing in cancer risk management

Discover how genetic testing can empower you to take control of your health by understanding your inherited cancer risks and taking proactive measures with NHS-supported tests.